Skip Navigation



NDT Advance Access published online on February 13, 2007

Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfl839
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
22/5/1332    most recent
gfl839v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Chandar, J.
Right arrow Articles by Zilleruelo, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chandar, J.
Right arrow Articles by Zilleruelo, G.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2007]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Angiotensin blockade as sole treatment for proteinuric kidney disease in children

Jayanthi Chandar, Carolyn Abitbol, Brenda Montané and Gastón Zilleruelo

Department of Paediatrics, Division of Paediatric Nephrology, Holtz Children's Hospital, University of Miami Miller School of Medicine, 33101, Miami, USA

Correspondence and offprint requests to: Jayanthi Chandar, MD, Division of Paediatric Nephrology, University of Miami/Holtz Children's Hospital, P.O. Box 016960 (M-714), Miami, Florida 33101, USA. Email: jchanda2{at}med.miami.edu



  Abstract

Background. The traditional management of children with proteinuric kidney disease is treatment with high dose steroids regardless of comorbid conditions such as obesity. This study evaluated the effect of angiotensin blockade (AB) alone as the sole management of children with non-diabetic proteinuric kidney disease.

Methods. Retrospective chart analysis was performed in 146 children. Seventeen were identified to have received angiotensin-converting enzyme inhibitor and/or angiotensin receptor blocker exclusively for management of proteinuria. Total proteinuria (Upr/cr), albuminuria (Ualb/cr), estimated glomerular filtration rate (eGFR), serum potassium and blood pressure were assessed at baseline and at 3–month intervals for over 24 months.

Results. Mean age was 11.2 ± 4.8 years with 12 females. Eleven of 17 patients (65%) were overweight or obese. There was a significant decline in total proteinuria and albuminuria after 3–6 months of AB therapy and a further decline with longer duration of treatment (P < 0.001). Although single vs dual AB were similarly effective in lowering total proteinuria, dual therapy was more effective in lowering albuminuria (single 57 ± 23% vs dual 71 ± 15%; P < 0.02). The eGFR decreased from ‘hyperfiltration’ levels prior to initiation of AB to normal at the end of the treatment period (145 ± 41–111 ± 17 ml/min/1.73m2; P = 0.01). Systemic blood pressures remained normal throughout the study period.

Conclusions. Angiotensin blockade alone appears to effectively control proteinuria and stabilize kidney function in children. This may provide an alternative to more toxic therapies, especially corticosteroids, in children with glomerular disorders such as those associated with obesity.

Keywords: albuminuria; angiotensin blockade; hyperfiltration; obesity; proteinuria

Received for publication: 3.10.06
Accepted in revised form: 26.12.06


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
L. M. Bivol, R. K. Berge, and B. M. Iversen
Tetradecylthioacetic acid prevents the inflammatory response in two-kidney, one-clip hypertension
Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2008; 294(2): R438 - R447.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.